RxDoctor Payments DataLook up a doctor →

Maria Marrero, NP

Family · Dyer, INNPI 1396122784

Payments from drug & device makers

$18,134in general payments, 2019–2025

Across 600 payments — averaging $30.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Daiichi Sankyo Inc.$2K
  • AstraZeneca$1K
  • Dova Pharmaceuticals$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Regeneron Healthcare Solutions, Inc.$898
  • plus $10K from 53 others

What the payments were for

  • Consulting fees$1,5008%
  • Speaking & faculty fees$1,4008%
  • Food & beverage$13,63175%
  • Education$6213%
  • Other$9825%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis52$1,803
Daiichi Sankyo Inc.10$1,692
AstraZeneca63$1,423
Dova Pharmaceuticals3$1,419
E.r. Squibb & Sons, L.L.C.57$1,192
Regeneron Healthcare Solutions, Inc.19$898
Amgen30$832
AbbVie25$612
Bristol Myers Squibb39$607
Merck27$564
Genentech USA, Inc.30$553
Pfizer32$534
Incyte Corporation22$507
Jazz Pharmaceuticals Inc.7$441
Johnson & Johnson(2 entities)10$418
Sanofi18$323
Astellas Pharma US Inc14$315
Seagen Inc.8$311
Pharmacyclics LLC, An Abbvie Company12$295
Rigel Pharmaceuticals, Inc.14$292
Eisai Inc.15$289
Karyopharm Therapeutics Inc.8$257
Gilead(2 entities)9$181
Tactile Systems Technology Inc2$157
Beigene USA, Inc.6$157
Array Biopharma Inc6$142
AMAG Pharmaceuticals, Inc.2$138
Puma Biotechnology, Inc.2$125
Immunogen, Inc.1$125
Mirati Therapeutics, Inc.1$121
Deciphera Pharmaceuticals Inc.6$117
Adaptive Biotechnologies Corporation4$112
Takeda Pharmaceuticals U.S.A., Inc.4$103
Stryker2$102
Tempus AI, Inc1$94
Sobi, Inc5$92
GSK4$86
Geron Corporation2$70
ADC Therapeutics America, Inc.1$58
Bayer3$57
AVEO Pharmaceuticals, Inc.3$54
Sumitomo Pharma America, Inc.2$51
Exelixis Inc.1$50
EMD Serono, Inc.2$36
Syndax Pharmaceuticals, Inc.1$32
Pharmaessentia USA Corporation2$29
Myovant Sciences Inc.1$29
Servier Pharmaceuticals LLC1$24
Boehringer Ingelheim1$23
Global Blood Therapeutics, Inc.1$22
Azurity Pharmaceuticals, Inc.1$22
Alnylam Pharmaceuticals Inc.1$21
Lilly USA, LLC1$21
Tolmar, Inc.1$21
Ipsen Biopharmaceuticals, Inc1$21
Acrotech Biopharma Inc.1$18
Pharmacosmos Therapeutics Inc.1$18
Tersera Therapeutics LLC1$17
Kyowa Kirin, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,134 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$109,505
Medicare patients
153
Services billed
2,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide24$322,703
BrukinsaZanubrutinib18$206,599
ImbruvicaIbrutinib12$196,053
JakafiRuxolitinib Phosphate11$189,152
TasignaNilotinib Hcl13$146,127
XareltoRivaroxaban41$56,807
EliquisApixaban42$35,636
SiklosHydroxyurea12$10,496
Exemestane19$5,854
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$1,442
Anastrozole66$1,116
Enoxaparin Sodium13$721
Warfarin Sodium43$678
Acyclovir37$643
Potassium Chloride59$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$315$322,70324 claims
Beigene USA, Inc.Brukinsa$157$206,59918 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$295$196,05312 claims
Incyte CorporationJakafi$507$189,15211 claims
NovartisTasigna$1,803$146,12713 claims
Johnson & JohnsonXarelto$418$56,80741 claims
PfizerEliquis$534$35,63642 claims
Lilly USA, LLCOlanzapine$21$42611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →